Literature DB >> 1942193

Pneumocystis carinii pneumonia.

P C Goodman1.   

Abstract

Pneumocystis carinii pneumonia (PCP) is the most common index diagnosis in patients with acquired immunodeficiency syndrome (AIDS). Eighty percent of AIDS patients will eventually develop PCP. Common presenting symptoms are shortness of breath, cough, weight loss, and fever. The chest radiograph typically reveals a diffuse, bilateral, symmetric, fine-to-medium reticulonodular pattern of opacities. Upper lobe disease has been reported recently in patients who have undergone prophylactic therapy with aerosolized pentamidine. Pneumatoceles, or thin-walled air-containing cysts, have been noted in 10% of patients with PCP. Lymphadenopathy and pleural effusion are extremely rare. Therapy with various agents is generally successful, resulting in clinical and radiographic improvement within 7 to 10 days. Recurrence of PCP is common.

Entities:  

Mesh:

Year:  1991        PMID: 1942193     DOI: 10.1097/00005382-199109000-00006

Source DB:  PubMed          Journal:  J Thorac Imaging        ISSN: 0883-5993            Impact factor:   3.000


  3 in total

Review 1.  Illustration of a number of atypical computed tomography manifestations of active pulmonary tuberculosis.

Authors:  Yi Zeng; Xiao-Li Zhai; Yì Xiáng J Wáng; Wei-Wei Gao; Chun-Mei Hu; Fei-Shen Lin; Wen-Shu Chai; Jian-Yun Wang; Yan-Ling Shi; Xin-Hua Zhou; Hui-Shan Yu; Xi-Wei Lu
Journal:  Quant Imaging Med Surg       Date:  2021-04

2.  Single nodular opacity of granulomatous pneumocystis jirovecii pneumonia in an asymptomatic lymphoma patient.

Authors:  Hyun Soo Kim; Kyung Eun Shin; Ju-Hie Lee
Journal:  Korean J Radiol       Date:  2015-02-27       Impact factor: 3.500

3.  Characteristics of risk factors for acute kidney injury among inpatients administered sulfamethoxazole/trimethoprim: a retrospective observational study.

Authors:  Yuki Shimizu; Toshinori Hirai; Yukari Ogawa; Chihiro Yamada; Emiko Kobayashi
Journal:  J Pharm Health Care Sci       Date:  2022-08-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.